IMMUNOPHARMA AS

Operating

ImmunoPharma — Research-based company targeting immune stimulating substances

Utvikle, distribuere og selge ernæringsprodukter og farmasøytiske produkter samt tilknyttede tjenester med mer, samt investering i annen virksomhet.

Keywords

advertising businesscreative businessproductionadvertising materialarrangementimplementationadvertising campaignsdesignplacementadvertisementsnewspapersmagazinesradio and televisioninternetoutdoor advertisingbillboardsposterswindow displayinterior designshowroomscarsbusesaerial advertisingdistributiondeliverypromotional materialsamplesprocurementracksmarketing campaignsmarketing consultancy

Organization

Chairman of the board: KR
Kjetil Ramsøy1971
Years since formation: 16 years; since Jan 4, 2010
Type: Limited company
VAT registered: Yes
Number of employees: 15

Ownership

Number of shares and share classes: 138,654,422; 1 share class
Total number of shareholders: 74; 32 companies, 42 persons
Belongs to group of

Financials

Total operating income 2025: 18,004,610; NOK
Annual total result 2025: -4,514,135; NOK
Total equity 2025: 204,510,579; NOK

Last update: Jul 15, 2026

Management

Board

Name	Role	Shares
KR Kjetil Ramsøy 1971	Chairman	-
PJ Piotr Jerzy Sierdzinski 1978	Alternate Member	-
FM Frode Marc Bohan 1968	Board Member	-

Others

Name	Role	Shares
F FORVIS MAZARS AS	Auditor	-

Top 10 individual shareholders

Name	Role	Shares
FM Frode Marc Bohan 1968	-	35.45 % indirectly
KØ Kim Øien 1968	-	23.57 % indirectly
ST Sjur Thorsheim 1958	-	1.6 % indirectly
HN Henning Normann Fjøs 1965	-	1.44 % indirectly
KC Knut Christian Espeseth 1965	-	1.23 % indirectly

Last update: Jan 22, 2026

Ownership

Company shareholders

Name	Share class	Total number of shares	Share
B BOHAN & CO AS	NO0010735335	49,146,837	35.45 %
N NICOLINE INVEST AS	NO0010735335	32,685,935	23.57 %
SA Sis Ag Six	NO0010735335	8,891,077	6.41 %
LS Labs Sp Zoo Ska Equity	NO0010735335	8,193,875	5.91 %
SA Switzerland Ag Ubs	NO0010735335	7,130,357	5.14 %
HA Handelsbanken Ab Svenska	NO0010735335	3,465,611	2.5 %
N NORDIC HEALTHY LIVING AS	NO0010735335	2,673,697	1.93 %
P PRO AS	NO0010735335	2,222,222	1.6 %
T THEO INVESTMENTS AS	NO0010735335	2,144,444	1.55 %
V VESTMARK RESEARCH CONSULTING AS	NO0010735335	2,000,000	1.44 %
N NOXA AS	NO0010735335	2,000,000	1.44 %
3 3LP NORGE AS	NO0010735335	1,724,901	1.24 %
R RHUMB LINE AS	NO0010735335	1,685,492	1.22 %
BA Bank Ab Avanza	NO0010735335	1,412,275	1.02 %
M MOMENTUM CONSULT & INVEST AS	NO0010735335	1,000,000	0.72 %
SO Stein Ole Vrenne 1966	NO0010735335	1,000,000	0.72 %
CB Clearstream Banking S.a.	NO0010735335	909,920	0.66 %
NF Nicolai Flatner 1969	NO0010735335	777,777	0.56 %
C CINCO INVEST AS	NO0010735335	750,000	0.54 %
E ENG AS	NO0010735335	741,250	0.53 %
P PVO INVEST AS	NO0010735335	666,666	0.48 %
L LT FINANS AS	NO0010735335	500,000	0.36 %
KB Kjetil Bjørkmann Ødven 1972	NO0010735335	445,000	0.32 %
J JAN FR. BJERKENES HOLDING AS	NO0010735335	444,444	0.32 %
AC Aktiengesellschaft Commerzbank	NO0010735335	439,000	0.32 %
L LANDMARK INVEST AS	NO0010735335	350,000	0.25 %
BA Bank As Danske	NO0010735335	348,824	0.25 %
TN Trygve Nielsen 1964	NO0010735335	333,333	0.24 %
RM Roger Morten Mortensen 1967	NO0010735335	333,333	0.24 %
SK Salo Kristiansen Terje	NO0010735335	330,000	0.24 %
I IMMUNOPHARMA AS	NO0010735335	275,000	0.2 %
C CARUSO HOLDING AS Closed	NO0010735335	267,858	0.19 %
T TEAM6 AS	NO0010735335	250,000	0.18 %
M MIL INVEST AS	NO0010735335	222,222	0.16 %
BA Bank Austria Ag Unicredit	NO0010735335	222,222	0.16 %
L LJM AS	NO0010735335	222,222	0.16 %
AS Ab Swedbank	NO0010735335	154,172	0.11 %
K KLEIVO HOLDING AS	NO0010735335	150,000	0.11 %
H HELM STYRBORD AS	NO0010735335	142,000	0.1 %
JB Julius Bär Co Ag Bank	NO0010735335	140,000	0.1 %
LV Ludovico-Enrico Vitali-Rosati 1962	NO0010735335	133,929	0.1 %
VF Vidar Femdal Røe 1968	NO0010735335	133,929	0.1 %
VJ Vincent Jacob Jebsen 1944	NO0010735335	133,929	0.1 %
BA Bank Ab Nordnet	NO0010735335	118,479	0.09 %
G GRANSJØEN AS	NO0010735335	111,111	0.08 %
OH Ole Hansen 1965	NO0010735335	111,111	0.08 %
R RED GRUPPEN AS	NO0010735335	111,111	0.08 %
N Nest Trading A/S	NO0010735335	102,200	0.07 %
IT Inge Toralf Nilsen 1961	NO0010735335	100,000	0.07 %
H HIPPOGRIFF AS	NO0010735335	100,000	0.07 %
KA Kjell Arthur Neset 1961	NO0010735335	76,700	0.06 %
BA Bank Aktiengesellschaft Deutsche	NO0010735335	70,000	0.05 %
TN Trond Nesheim 1969	NO0010735335	56,049	0.04 %
SG Stein Grende 1952	NO0010735335	50,000	0.04 %
V VANGEN BIL AS	NO0010735335	50,000	0.04 %
TE Terje Erikstad 1984	NO0010735335	41,595	0.03 %
HL Haakon Lude Sande 1978	NO0010735335	40,000	0.03 %
K K&S INVEST AS	NO0010735335	37,500	0.03 %
IA Ingolfur Arnar Sigfusson 1955	NO0010735335	36,600	0.03 %
LJ Leidulv Johan Grytten 1948	NO0010735335	35,000	0.03 %
ML Marit Lambrechts 1957	NO0010735335	34,638	0.02 %
CV Cantonale Vaudoise Banque	NO0010735335	30,000	0.02 %
R RYSSEVIK INVEST LTD NUF	NO0010735335	23,266	0.02 %
EV Erlend Vatne 1972	NO0010735335	22,222	0.02 %
DE Diana Emilie Charlotte Jandl Von Hall 1970	NO0010735335	20,000	< 0.01 %
MT Magnar Tveite 1964	NO0010735335	17,086	< 0.01 %
MR Maria R Laishley Sandbu 1983	NO0010735335	12,000	< 0.01 %
C CAPTIVIA FINANS AS	NO0010735335	11,000	< 0.01 %
BA Bank Ag Lgt	NO0010735335	10,000	< 0.01 %
TL Torgrim Ljones 1938	NO0010735335	10,000	< 0.01 %
MO Marius Oliver Ramsøy Godø 1990	NO0010735335	9,000	< 0.01 %
HS Hannah Strøm-Pedersen 1995	NO0010735335	9,000	< 0.01 %
BA Bank Austria Ag Unicredit	NO0010735335	5,000	< 0.01 %
G GENZEB LIMITED NUF	NO0010735335	1	< 0.01 %

Shares owned by the IMMUNOPHARMA AS

Name	Share class	Total number of shares	Share
I IP EQOLOGY HOLDCO AS	Ordinary shares	20,000,000	100 %
N NATTOPHARMA AS	NO0010289200	350,000	100 %
N NORDIC HEALTHY LIVING AS	Ordinary shares	2,241,918	100 %
M MYCOTECH PHARMA AS	Ordinary shares	110,330,000	97.77 %
S SMARTFISH AS	NO0010604838	33,695,080	80.21 %
I IMMUNOPHARMA AS	NO0010735335	275,000	0.2 %

Last update: Jun 2, 2025

Group structure

IMMUNOPHARMA AS
Total operating income 2025: NOK 18,004,610
Operating profit 2025: NOK -20,461,195
Employees: 15

Financials

in NOK

Summary

Year	2025	2024	2023	2022	2021
Total operating income	18,004,610	12,205,647,000	14,110,340	21,058,663	11,478,057
Annual Total Result	-4,514,135	13,723,672,000	-109,703,887	36,733,018	-37,953,672
Total assets	393,197,113	338,081,366,000	267,015,068	367,491,391	358,690,144
Total liabilities	188,686,535	129,056,652,000	71,714,026	62,163,914	102,524,100
Total equity	204,510,579	209,024,714,000	195,301,042	305,327,477	256,166,044

P&L

Year	2025	2024	2023	2022	2021
Total operating income	18,004,610	12,205,647,000	14,110,340	21,058,663	11,478,057
Total operating costs	38,465,806	50,722,916,000	27,078,091	27,740,900	27,617,542
Operating result	-20,461,195	-38,517,269,000	-12,967,751	-6,682,237	-16,139,485
Financial income/costs	15,562,496	57,211,333,000	-87,367,218	42,029,065	-24,949,462
Profit before tax	-4,898,699	18,694,064,000	-100,334,969	35,346,828	-41,088,947
Total tax & extraordinary income/cost	-384,564	4,970,392,000	9,368,918	-1,386,190	-3,135,275
Annual Total Result	-4,514,135	13,723,672,000	-109,703,887	36,733,018	-37,953,672

Balance overview

Year	2025	2024	2023	2022	2021
Total fixed assets	357,297,771	265,392,221,000	201,120,676	359,976,449	314,236,860
Total current assets	35,899,343	72,689,145,000	65,894,392	7,514,942	44,453,284
Total assets	393,197,113	338,081,366,000	267,015,068	367,491,391	358,690,144
Short term debt	188,010,669	128,672,088,000	71,236,949	34,085,452	61,124,698
Long term debt	675,866	384,564,000	477,077	28,078,462	41,399,402
Total liabilities	188,686,535	129,056,652,000	71,714,026	62,163,914	102,524,100
Contributed capital	204,510,579	327,503,068,000	327,503,068	327,825,617	315,549,609
Retained earnings	0	-118,478,354,000	-132,202,026	-22,498,140	-59,383,565
Total equity	204,510,579	209,024,714,000	195,301,042	305,327,477	256,166,044
Total equity and liabilities	393,197,113	338,081,366,000	267,015,068	367,491,391	358,690,144

Classification

21st company classification

BETA

Individual SMB enterprise

IMMUNOPHARMA AS994 924 273

IMMUNOPHARMA AS

Keywords

Links

Organization

Ownership

Financials

Management

Board

Others

Top 10 individual shareholders

Ownership

Company shareholders

Shares owned by the IMMUNOPHARMA AS

Group structure

Financials

Summary

P&L

Balance overview

Classification